Cadence Plans FDA Meeting To Discuss Mixed Trial Results For IV Acetaminophen
This article was originally published in The Pink Sheet Daily
Executive Summary
One of two Phase III trials for Acetavance met its primary endpoint, while a second missed its mark.
You may also be interested in...
Alpharma Ups Ante With Phase III Embeda Proof
Pain drug’s data could help lure more than King to the table.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.